The type II transmembrane serine protease, matriptase-2: Possible links to cancer?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 64-69

  Sanders, Andrew J ^a   Webb, Siobhan L ^a   Parr, Christian ^a   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Breast cancer; Matriptase 2; Prostate cancer; TMPRSS 6; TTSP

Indexed keywords

DESC 1 PROTEIN; FERROPORTIN; HEMOJUVELIN; HEPSIN; IRON; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR CLASS A; MATRIPTASE; MATRIPTASE 2; PROCOLLAGEN C PROTEINASE; PROTEIN; TMPRSS6 PROTEIN; UNCLASSIFIED DRUG; URCHIN EMBRYONIC FACTOR; UROKINASE;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL COMMUNICATION; CELL INVASION; CELL MIGRATION; CHROMOSOME 22Q; ENZYME ACTIVITY; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; HAIR LOSS; HETEROZYGOSITY LOSS; HUMAN; INTERNALIZATION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; KIDNEY; LEYDIG CELL; LIVER; METASTASIS; MICROARRAY ANALYSIS; MISSENSE MUTATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UTERUS;

EID: 77950841852     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009010064     Document Type: Review

References (42)

1. Velasco, G.; Cal, S.; Quesada, V.; Sánchez, L. M.; López-Qtin, C. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J. Biol. Chem., 2002, 277, 37637-37646.
2. Hooper, J. D.; Campagnolo, L.; Goodarzi, D.; Truong, T. N.; Stuhlmann, H.; Quigley, J. P. Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult embryonic tissue. Biochem. J., 2003, 373, 689-702.
3. Beliveau, F.; Desilets, A.; Leduc, R. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides. FEBS J., 2009, 276, 2213-2226.
4. Silvestri, L.; Pagani, A.; Nai, A.; Domenico, I. D.; Kaplan, J.; Camaschella, C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab., 2008, 8, 1-10.
5. Du, X.; She, E.; Gelbart, T.; Truksa, J.; Lee, P.; Xia, Y.; Khovananth, K.; Mudd, S.; Mann, N.; Marie, E.; Moresco, Y.; Beutler, E.; Beutler, B. The serine protease TMPRSS6 is required to sense iron deficiency. Science, 2008, 320, 1088-1092.
6. Nemeth, E.; Tuttle, M. S.; Powelson, J.; Vaughn, M. B.; Donovan, A.; Ward, D. M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, 306, 2090-2093.
7. Folgueras, A. R.; Lara, F. M. d.; Pendas, A. M.; Garabaya, C.; Rodriguez, F.; Astudillo, A.; Bernal, T.; Cabanillas, R.; Lopez- Otin, C.; Velasco, G. Membrane-bound serine protease matriptase- 2 (Tmprss6) is an essential regulator of iron homeostasis. Blood, 2008, 112, 2539-2545.
8. Melis, M. A.; Cau, M.; Cangiu, R.; Sole, G.; Barella, S.; Cao, A.; Westerman, M.; Cazzola, M.; Galanello, R. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica, 2008, 93, 1473-1479.
9. Silvestri, L.; Guillem, F.; Pagani, A.; Nai, A.; Oudin, C.; Silva, M.; Toutain, F.; Kannengiesser, C.; Beaumont, C.; Camaschella, C.; Grandchamp, B. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associatedwith iron-refractory iron deficiency anemia. Blood, 2009, 113, 5605-5608.
10. Samad, T. A.; Rebbapragada, A.; Bell, E.; Zhang, Y.; Sidis, Y.; Jeong, S. J.; Campagna, J. A.; Perusini, S.; Fabrizio, D. A.; Schneyer, A. L.; Lin, H. Y.; Brivanlou, A. H.; Attisano, L.; Woolf, C. J. DRAGON, a bone morphogenetic protein co-receptor. J. Biol. Chem., 2005, 280, 14122-14129.
11. Babitt, B. L.; Zhang, Y.; Samad, T. A.; Xia, Y.; Tang, J.; Campagna, J. A.; Schneyer, A. L.; Woolf, C. J.; Lin, H. Y. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J. Biol. Chem., 2005, 280, 29820-29827.
12. Babitt, J. L.; Huang, F. W.; Wrighting, D. M.; Xia, Y.; Sidis, Y.; Samad, T. A.; Campagna, J. A.; Chung, R. T.; Schneyer, A. L.; Woolf, C. J.; Andrews, N. C.; Lin, H. Y. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet., 2006, 38, 531-539.
13. Wallrapp, C.; Hanel, S.; Muller-Pillasch, F.; Burghardt, B.; Iwamura, T.; Ruthenburger, M.; Lerch, M. M.; Adler, G.; Gress, T. M. A novel transmembrane serine protease (tmprss3) overexpressed in pancreatic cancer. Cancer Res., 2000, 60, 2602-2606.
14. Lee, J.-W.; Song, S. Y.; Choi, J.-J.; Lee, S.-J.; Kim, B.-G.; Park, C.-S.; Lee, J.-H.; Lin, C.-Y.; Dickson, R. B.; Bae, D.-S. Increased expression of Matriptase is associated with histopathologic grades of cervical neoplasia. Hum. Pathol., 2005, 36, 626-633.
15. Magee, J. A.; Araki, T.; Patil, S.; Ehrig, T.; True, L.; Humphrey, P. A.; Catalona, W. J.; Watson, M. A.; Milbrandt, J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res., 2001, 61, 5692-5696.
16. Hoang, C. D.; D'Cunha, J.; Kratzke, M. G.; Casmey, C. E.; Frizelle, S. P.; Maddaus, M. A.; Kratzke, R. A. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest, 2004, 125, 1843-1852.
17. Netzel-Arnett, S.; Hooper, J. D.; Szabo, R.; Madison, E. L.; Quigley, J. P.; Bugge, T. H.; Antalis, T. M. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev., 2003, 22, 237-258.
18. Lang, J. C.; Schuller, D. E. Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br. J. Cancer, 2001, 84, 237-243.
19. Mori, Y.; Kono, K.; Matsumoto, Y.; Fujii, H.; Yamane, T.; Mitsumata, M.; Chen, W. T. The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology, 2004, 67, 411-419.
20. Santin, A. D.; Zhan, F.; Bellone, S.; Palmieri, M.; cane, S.; Bignotti, E.; Anfossi, S.; Gokden, M.; Dunn, D.; Roman, J. J.; O'Brien, T. J.; Tian, E.; Cannon, M. J.; Shaughnessy, J.; Pecorelli, S. Gene expression profiles in primary ovarian serous papillary tumours and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer, 2004, 112, 14-25.
21. Uhland, K. Matriptase and its putative role in cancer. Cell. Mol. Life Sci., 2006, 63, 2968-2978.
22. Förbs, D.; Thiel, S.; Stella, M. C.; Stürzebecher, A.; Schweinitz, A.; Steinmetzer, T.; Stürzebecher, J.; Uhland, K. In vitro inhibition of Matriptase prevents invasive growth of cell lines of prostate and colon carcinomas. Int. J. Oncol., 2005, 27, 1061-1070.
23. Sanders, A. J.; Parr, C.; Davies, G.; Martin, T. A.; Lane, J.; Mason, M. D.; Jiang, W. G. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. J. Exp. Ther. Oncol., 2006, 6, 39-48.
24. Galkin, A. V.; Mullen, L.; Fox, W. D.; Brown, J.; Duncan, D.; Moreno, O.; Madison, E. L.; Agus, D. B. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate, 2004, 61, 228-235.
25. Allione, F.; Eisinger, F.; Parc, P.; Noguchi, T.; Sobol, H.; Birnbaum, D. Loss of heterozygosity at loci from chromosome arm 22q in human sporadic breast carcinomas. Int. J. Cancer, 1998, 75, 181-186.
26. Iida, A.; Kurose, K.; Isobe, R.; Akiyama, F.; Sakamoto, G.; Yoshimoto, M.; Kasumi, F.; Nakamura, Y.; Emi, M. Mapping of a new target region of allelic loss to a 2-cm interval at 22q13.1 in primary breast cancer. Genes Chromosomes Cancer, 1998, 21, 108-112. (Pubitemid 28081236)
27. Castells, A.; Gusella, J. F.; Ramesh, V.; Rustgi, A. K. A region of deletion on chromosoem 22q13 is common to human breast and colorectal Cancers. Cancer Res., 2000, 60, 2836-2839.
28. Hirano, A.; Emi, M.; Tsuneizumi, M.; Utada, Y.; Yoshimoto, M.; Kasumi, F.; Akiyama, F.; Sakamoto, G.; Haga, S.; Kajiwara, T.; Nakamura, Y. Allelic losses of locia at 3p25.1, 8p22, 13q12, 17p13.3, and 22q 13 correlate with postoperative recurrence in breast cancer. Clin. Cancer Res., 2001, 7, 876-882.
29. Hartikainen, J. M.; Tuhkanen, J.; Kataja, V.; Eskelinen, M.; Uusitupa, M.; Kosma, V.-M.; Mannermaa, A. Refinement of the 22q12-q13 breast cancer-associated region: evidence of tmprss6 as a candidate gene in an eastern Finnish population. Clin. Cancer Res., 2006, 12, 1454-1462.
30. Odet, F.; Verot, A.; Magueresse-Battistoni, B. L. The mouse testis is the source of various serine proteases and serine proteinase inhibitors (SERPINs): Serine proteases and SERPINs identified in leydig cells are under gonadotropin regulation. Endocrinology, 2006, 147, 4374-4383.
31. Overall, C. M.; Tam, E. M.; Kappelhoff, R.; Connor, A.; Ewart, T.; Morrison, C. J.; Puente, X.; Lopez-Otin, C.; Seth, A. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem., 2004, 385, 493-504.
32. Parr, C.; Sanders, A. J.; Davies, G.; Martin, T.; Lane, J.; Mason, M. D.; Mansel, R. E.; Jiang, W. G. Matriptase-2 inhibits breast tumour growth and invasion and correlates with favourable prognosis for breast cancer patients. Clin. Cancer Res., 2007, 13, 3568-3576.
33. Sanders, A. J.; Parr, C.; Martin, T. A.; Lane, J.; Mason, M. D.; Jiang, W. G. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J. Cell. Physiol., 2008, 216, 780-789.
34. Lee, S. L.; Dickson, R. B.; Lin, C. Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem., 2000, 275, 36720-36725.
35. Takeuchi, T.; Harris, J. L.; Huang, W.; Yan, K. W.; Coughlin, S. R.; Craik, C. S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single- chain urokinase-type plasminogen activator as substrates. J. Biol. Chem., 2000, 275, 26333-26342.
36. Parr, C.; Jiang, W. G. Expression of hepatocyte growth factor/ scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol., 2001, 19, 857-863.
37. Davies, G.; Mason, M. D.; Martin, T. A.; Parr, C.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Jiang, W. G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF- induced prostate tumour growth and angiogenesis in vivo. Int. J. Cancer, 2003, 106, 348-354.
38. Martin, T. A.; Parr, C.; Davies, G.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Mansel, R. E.; Jiang, W. G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis, 2003, 24, 1317-1323.
39. Parr, C.; Jiang, W. G. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int. J. Cancer, 2006, 119, 1176-1183.
40. Moreno-Miralles, I.; Schisler, J. C.; Pattersnon, C. New insights into bone morphogenetic protein signaling: focus on angiogenesis. Curr. Opin. Hematol., 2009, 16, 195-201.
41. Bokobza, S. M.; Ye, L.; Jiang, W. G. When BMP signalling goes wrong: The intracellular and molecular mechanisms of BMP signalling in cancer. Curr. Signal Transduct. Ther., 2009, 4, 174-195.
42. Bailey, J. M.; Singh, P. K.; Hollingsworth, M. A.. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, notch and bone morphogenic proteins. J. Cell. Biol., 2007, 102, 829-839.